In the News

For press inquiries: teamritedose@mcalistercommunications.com

Ritedose Launches New 503B, Single-Dose Syringe Medications for Hospitals: Rocuronium Bromide Injection (50 mg/5mL) and Rocuronium Bromide Injection (100 mg/10mL)

COLUMBIA, S.C. (February 14, 2022) – Ritedose, a 25-year industry veteran in pharmaceutical development and cGMP manufacturing, just launched two new 503B critical care, unit dose syringe products – Rocuronium Bromide Injection 50 mg/5mL and Rocuronium Bromide Injection 100 mg/10mL. Ritedose 503B Outsourcing Facility is a division of Ritedose.

Read More »

The Ritedose Corporation Announces Revolutionary Liquid Med Dispenser
SuredoseRx™ to launch in first quarter

COLUMBIA, S.C. (January 18) — The Ritedose Corporation has announced the development of and plans to commercialize the first new way to dispense single-dose liquid medications in two decades. After five years of R&D, the Columbia-based developer of blow-fill-seal unit dose technology is launching SuredoseRx™, an easier and more convenient way for healthcare workers to administer, and patients to take, single doses of liquid medications.

Read More »

Ritedose Pharmaceuticals Launches Cromolyn Sodium Oral Solution (Concentrate) 100 mg/5 ml

COLUMBIA, S.C. (January 5, 2022) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product, Cromolyn Sodium Oral Solution (Concentrate), 100 mg/5 ml. The oral solution is the first of a new product line for Ritedose Pharmaceuticals which has historically offered a portfolio of generic inhalation solutions. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies, research development programs, hospitals, wholesalers and pharmacies.

Read More »

Novo Holdings to acquire Ritedose:
Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire Ritedose from AGIC Capital and Humanwell.

COPENHAGEN, Denmark, Jan. 4, 2022 /PRNewswire/ – Founded in 1995 and headquartered in Columbia, S.C., The Ritedose Corporation (“Ritedose”) is a leading sterile pharmaceutical manufacturer, specialising in the use of blow-fill-seal (BFS) technology. Ritedose provides outsourced development and manufacturing of ophthalmology drugs, respiratory drugs, and vaccines.

Read More »

Ritedose Pharmaceuticals Launches Budesonide Inhalation Suspension (0.5 mg/2 ml)

COLUMBIA, S.C. (December 29, 2021) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product for hospitals, Budesonide Inhalation Suspension (0.5 mg/2 ml). It is the first of five new inhalation products scheduled for release by March 2022. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies, research development programs, hospitals, wholesalers and pharmacies.

Read More »

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL)

COLUMBIA, S.C. (September 10, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL). It is the last of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: Epinephrine Injection 1 mg/10 mL (0.1 mg/mL)

COLUMBIA, S.C. (August 24, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Epinephrine Injection 1 mg/10 mL (0.1 mg/mL). It is the 11th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: Sodium Chloride Injection 23.4% (120mEq/30 mL)

COLUMBIA, S.C. (August 11, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Sodium Chloride Injection 23.4% (120mEq/30 mL). It is the 10th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Pioneers in aseptic production of sterile, single-dose medication